UTHR

Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606.

In a comparison of two medical-drugs stocks, Shionogi & Co., Ltd. (SGIOY) emerges as the superior value option compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 10.68 versus UTHR's 20.59, and a more favorable P/B ratio of 1.34 compared to UTHR's 3.64. UTHR carries a Zacks Rank #3 (Hold) with a Value grade of C.

The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports.

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share.

Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.